首页> Investigational new drugs> A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma.

A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma.

导出原文传递

翻译打印收藏纠错

第一作者： Daniel H,Ahn

第一单位： Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA.

作者： Daniel H,Ahn ^[1] ; Pedro Luiz Serrano,Uson Junior ^[2] ; Peter,Masci ^[1] ; Heidi,Kosiorek ^[3] ; Thorvardur R,Halfdanarson ^[4] ; Kabir,Mody ^[5] ; Hani,Babiker ^[5] ; Thomas,DeLeon ^[1] ; Mohamad Bassam,Sonbol ^[1] ; Gregory,Gores ^[6] ; Rory,Smoot ^[4] ; Tanios,Bekaii-Saab ^[1] ; Amit,Mahipal ^[4] ; Aaron,Mansfield ^[4] ; Nguyen H,Tran ^[4] ; Joleen M,Hubbard ^[4] ; Mitesh J,Borad ^[7]

作者单位： Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA. ^[1] Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA.;Hospital Israelita Albert Einstein, São Paulo, SP, Brazil. ^[2] Division of Biostatistics and Informatics, Mayo Clinic, Phoenix, AZ, USA. ^[3] Department of Hematology/Oncology, Mayo Clinic, Rochester, MN, USA. ^[4] Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA. ^[5] Division of Gastroenterology, Mayo Clinic, Rochester, MN, USA. ^[6] Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA. borad.mitesh@mayo.edu.;Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA. borad.mitesh@mayo.edu.;Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA. borad.mitesh@mayo.edu.;Mayo Clinic Cancer Center, Phoenix, AZ, USA. borad.mitesh@mayo.edu. ^[7]

关键词 Bile duct cancers Cholangiocarcinoma FGFR Next generation sequencing Ponatinib Targetable mutations